Brief: CE Approval For Xvivo's Perfusion Solution For Heart Preservation Is Delayed
July 29 (Reuters) - Xvivo Perfusion AB XVIVO.ST: SAID ON MONDAY XVIVO HEART ASSIST TRANSPORT AND XVIVO HEART ASSIST TRANSPORT PERFUSION SET HAVE RECEIVED CE APPROVAL ESTIMATES DELAYS OF 6-12 MONTHS FOR CE APPROVAL OF XVIVO'S HEART PERFUSION SOLUTION AND SUPPLEMENT DUE TO CONSULTATION PROCESS AT EU COMPETENT AUTHORITY Source text for Workspace: nMFNc7yfBS Further company coverage: XVIVO.ST (Gdansk Newsroom) ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))
Recent news on Xvivo Perfusion AB
See all newsSweden's XVIVO Q3 revenue beat expectations on thoracic sales
Brief: Xvivo Q3 EBIT SEK 28 Million
Brief: Xvivo Receives CE Certificates For Heart Preservation Technology
Brief: XVIVO Gets FDA Approval For Additional Patient Enrollment
Sweden's XVIVO Q2 sales beat estimates, helped by thoracic segment strength